Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website
Subscribe CustomBlackClose

Belt & Road Weekly Subscription Form

download_pop

Research ReportCustomBlackClose

The full edition of the report is available at Xinhua Silk Road Database. You can click the “Table of Content” to have a general understanding of it.

Click on the button below to create your account and get immediate access to thousands of articles.

Start a Free Trial

Xinhua Silk Road Database
Info

Big potential for use of traditional Chinese medicine in U.S: experts

November 29, 2018


Abstract : Traditional Chinese medicine has big potential to become part of mainstream health service in the United States especially in the areas where Western medicine reaches its limitation, said several TCM experts. 

NEW YORK, Nov. 28 (Xinhua) -- Traditional Chinese medicine has big potential to become part of mainstream health service in the United States especially in the areas where Western medicine reaches its limitation, said several TCM experts. 

The existing Western medical therapies have difficulty in solving many medical problems, while TCM has been proven effective in treating diseases in its long history of practice in China, Xu Jianguang, president of Shanghai University of Traditional Chinese Medicine told Xinhua in an earlier interview. 

"We need to use the solid evidence, technology and data to demonstrate why and how Chinese medicine works and under what medical condition," said Xu, who is also an expert on hand surgery and microsurgery. 

Now, TCM products are mostly regulated as dietary supplement in the Untied States. But a number of TCM products have entered phase-two and even phase-three trials in application of new drugs with U.S. Food and Drug Administration (FDA). 

China's TCM product developer Tasly Pharmaceutical has been a frontrunner and entered phase-3 clinical trials for its TCM product T89, a kind of botanical cardiotonic pill. 

If FDA finally certifies T89 as a new drug, people could change their views on TCM and the possible breakthrough could fuel development of the TCM industry, said Aaron Zhu, general manager of Zhongke Health International (New York) LLC, which sells a series of botanical extract products as dietary supplement in the United States.

Still, it will take a long time for TCM to become part of mainstream health care services in the Untied States as TCM products are yet to be certified by FDA as drugs and the licensing of herbalist need to be introduced separately, said Zhu on Wednesday. 

Zhou said botanical products have very big market in the Untied States while his company now only focuses on botanical products related to TCM. 

The development of TCM shall be guided by traditional theories and more standardization work should be done, said Chen Yemeng, president of New York College of Traditional Chinese Medicine. He added that the theories of TCM have not been fully accepted in the United States though acupuncture and other TCM therapies are widely used here. 

Now, there are nearly 40,000 acupuncture practitioners in 47 U.S. states, according to Chen.  

TCM should be integrated into existing professional therapies in the U.S. health care sector as soon as possible in a bid to prompt its adoption, Chen told Xinhua. 

New York-based Memorial Sloan Kettering Cancer Center, the major and oldest private cancer center in the world, has established an integrative medicine center featuring the use of acupuncture, massage, mind-body therapies as well as classes and workshops. 

New York College of Traditional Chinese Medicine carries out teaching clinics at multiple sites and regular lectures for local commodity, which helps promote people's awareness of TCM, according to Chen. 

TCM is based on holistic view of human body and disease, which always sees the big picture and proves useful in treating chronic diseases and serving aged people in particular.

Scan the QR code and push it to your mobile phone

Keyword: Tasly

Reading:

Tasly remains China's 2019 National Tech Innovation Demonstration Enterprise

Business Brief

Tasly invests in Mesoblast, introduces two stem cell products

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to [email protected] and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial

Ask Us A Question belt & road login close

If you have any questions, please enter them in the box below.

Identifying code Reload

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to silkroadweekly@xinhua.org and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial